Altimmune (ALT) Earnings Analysis

Altimmune (ALT) has no confirmed upcoming earnings date. Last quarter (2026-03-05) it missed with EPS -0.27 USD vs -0.25 USD est (-8%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -3.02.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ALT next report earnings?

No confirmed upcoming earnings date is currently scheduled for ALT. This page updates as the calendar is published.

ALT earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-05-0.27 USD-0.25 USD-8%Miss
2025-11-06-0.21 USD-0.29 USD+27.6%Beat
2025-02-27-0.33 USD-0.34 USD+2.9%Beat
2024-08-08-0.35 USD-0.34 USD-2.9%Miss

Beat rate: 2/4 (50%) over reported quarters with consensus data.

ALT valuation and analyst view

Trailing P/E-3.02
Trailing EPS-0.7318 USD
Price / book1.23
Dividend yield0.00%
Market cap0.24B
Analyst consensusBuy (12 buy / 3 hold / 0 sell)
Avg price target6.25 USD

Related research pages

Frequently asked questions

When is Altimmune (ALT)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for ALT. This page updates as the calendar is published.

Did ALT beat earnings last quarter?

In its 2026-03-05 report, ALT posted EPS of -0.27 USD versus a -0.25 USD estimate — a miss of 8%.

What is ALT's earnings track record?

Over the last 4 reported quarters with consensus data, ALT beat estimates 2 times (50%).

What is ALT's current P/E ratio and EPS?

ALT trades at a trailing P/E of -3.02 on trailing EPS of -0.7317987272209057 USD.

What do analysts rate ALT?

Analyst consensus is "Buy" across 15 ratings (0 strong buy, 12 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 6.25 USD.